A paid, time-boxed deployment of Ryniant on one real, active small-molecule discovery program to prove that a tissue delivery goal can be translated into an executable, closed-loop DMTA workflow.
You are not outsourcing R&D to us. Your team remains the scientific decision-maker and executes wet lab work as usual. We deploy/configure the platform, run the workflow, and deliver traceable outputs and measurable results.
Fixed scope, timeline, deliverables. Structured engagement with measurable outcomes.
Success triggers Phase 2 with metrics-based conversion. Down payment credited.
Expanded deployment across multiple programs, tissues, and deeper integration.
We are not synthesizing compounds, running wet lab assays ourselves, or acting as the scientific approver. Program ownership stays with your team.
Define tissue goal, map workflow, identify decision rules, establish baseline, confirm assay timeline.
Configure tissue filtering, assay standardization, governance gates, reporting formats.
Run real iterations: design → prioritize → test plan → results processing → learn → human approval.
Compare performance vs baseline, identify bottlenecks, define Phase 2 scope and scaling plan.
LOI trigger tied to pre-agreed metrics. Includes Phase 2 scope, timeline, resourcing, and commercial terms. Down payment credited to Phase 2.